AFP and neoplasm: The major findings of this study included (1) the combination of anti-PD-1 and sorafenib demonstrated better tumor control, longer PFS and OS comparing with anti-PD-1 alone, (2) combination therapy did not increase grade 3/4 toxicities significantly, and (3) deeper AFP response was a surrogate marker for deeper image response.